Cargando…

GATA3 is downregulated in HCC and accelerates HCC aggressiveness by transcriptionally inhibiting slug expression

Mostrar otras versiones (1)

Previous studies have reported that GATA3 is downregulated in multiple types of tumours, including gastric cancer and osteosarcoma. The aim of this study was to explore whether GATA3 serves as a tumour suppressor to inhibit hepatocellular carcinoma (HCC) development. Tumour tissue specimens and adja...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhuoliang, Fang, Xingliang, Xie, Guilin, Zhu, Jinlong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856699/ https://www.ncbi.nlm.nih.gov/pubmed/33613720 http://dx.doi.org/10.3892/ol.2021.12492

Ejemplares similares

GATA3 is downregulated in HCC and accelerates HCC aggressiveness by transcriptionally inhibiting slug expression
por: Zhang, Zhuoliang, et al.
Publicado: (2021)

Molecular network of HCC aggressiveness
por: Kim, Sang Geon, et al.
Publicado: (2015)

HCC, diet and metabolic factors: Diet and HCC
por: Montella, Maurizio, et al.
Publicado: (2011)

A Liver Index and its Relationship to Indices of HCC Aggressiveness
por: Carr, Brian I, et al.
Publicado: (2016)

GATA3 is downregulated in osteosarcoma and facilitates EMT as well as migration through regulation of slug
por: Ma, Linjie, et al.
Publicado: (2018)

Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC
por: Wei, Yulong, et al.
Publicado: (2021)

HNRNPC downregulation inhibits IL‐6/STAT3‐mediated HCC metastasis by decreasing HIF1A expression
por: Liu, Danfei, et al.
Publicado: (2022)

Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression
por: Kotsari, Maria, et al.
Publicado: (2023)

A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients
por: Lu, Feng, et al.
Publicado: (2020)

Hepatocellular carcinoma: HCC
por: Blum, Hubert E.
Publicado: (2011)

Intratumor heterogeneity in HCC
por: Friemel, Juliane, et al.
Publicado: (2015)

Splenic Volume, an Easy-To-Use Predictor of HCC Late Recurrence for HCC Patients After Hepatectomy
por: Fang, Tongdi, et al.
Publicado: (2022)

HCC surveillance results in earlier HCC detection: results from an Indian cohort
por: Kohli, Anita, et al.
Publicado: (2014)

Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring
por: Sun, Na, et al.
Publicado: (2020)

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
por: Huang, Yan, et al.
Publicado: (2022)

NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway
por: Yu, SiZhe, et al.
Publicado: (2021)

Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet
por: Ganguly, Souradipta, et al.
Publicado: (2021)

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo
por: Wang, Wei, et al.
Publicado: (2014)

Aggressive primary gastric lymphoma (PGL) masquerading as hepatocellular cancer (HCC) in alcoholic cirrhosis
por: Ahmed, Moiz, et al.
Publicado: (2021)

Decision making in elderly HCC
por: Trovato, M A, et al.
Publicado: (2011)

The Epigenetic Regulation of HCC Metastasis
por: Han, Tae-Su, et al.
Publicado: (2018)

Strategies for HCC target discovery
por: Molina-Sánchez, Pedro, et al.
Publicado: (2017)

Inflammatory Mechanisms of HCC Development
por: Refolo, Maria Grazia, et al.
Publicado: (2020)

Human Hepatocellular Carcinoma (HCC)
por: Buonaguro, Luigi
Publicado: (2020)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

HCC diagnosis DFP report
Publicado: (2021)

Diabetes medications and risk of HCC
por: Plaz Torres, Maria Corina, et al.
Publicado: (2022)

HCC: RNA-Sequencing in Cirrhosis
por: Wang, Haoyu, et al.
Publicado: (2023)

Connexin 32 downregulation is critical for chemoresistance in oxaliplatin-resistant HCC cells associated with EMT
por: Yang, Yan, et al.
Publicado: (2019)

Lamp2 inhibits epithelial-mesenchymal transition by suppressing Snail expression in HCC
por: Zheng, Hao, et al.
Publicado: (2018)

Elevated Serum Uric Acid is Associated With Poor Survival in Advanced HCC Patients and Febuxostat Improves Prognosis in HCC Rats
por: Wu, Le, et al.
Publicado: (2021)

Integrative module analysis of HCC gene expression landscapes
por: Li, Hongshi, et al.
Publicado: (2020)

Comparison between using hepatocellular carcinoma (HCC) risk scores and the HCC national guideline to identify high‐risk chronic hepatitis B patients for HCC surveillance in Thailand
por: Rattananukrom, Chitchai, et al.
Publicado: (2022)

TR(4) nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression
por: Jin, Ren’an, et al.
Publicado: (2018)

Metformin Counteracts HCC Progression and Metastasis Enhancing KLF6/p21 Expression and Downregulating the IGF Axis
por: Vacante, Fernanda, et al.
Publicado: (2019)

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista, Davide, et al.
Publicado: (2021)

Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC
por: Zhou, Wei, et al.
Publicado: (2022)

Selenoprotein P inhibits cell proliferation and ROX production in HCC cells
por: Wang, Jianxin, et al.
Publicado: (2020)

HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway
por: Chen, Lu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c7eg9ivi50a9e63bph6booqo08